Navigation Links
Onyx Pharmaceuticals Files Complaint Against Bayer Corporation
Date:5/17/2009

Asserts Rights to Phase 2 Anti-Cancer Compound Discovered During Joint Research

EMERYVILLE, Calif., May 17 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has filed a complaint in the United States District Court for the Northern District of California asserting its rights to a Phase 2 anti-cancer compound discovered during joint research between Onyx and Bayer. In its complaint, Onyx seeks a declaration that fluoro-sorafenib is a jointly-owned collaboration compound under the Bayer/Onyx collaboration agreement, together with other remedies. The defendants in the complaint are Bayer Corporation and Bayer A.G. Onyx affirmed that it continues to collaborate with Bayer in the development and commercialization of Nexavar.

Onyx was recently advised that the compound, fluoro-sorafenib, is a variant of Nexavar(R) (sorafenib) tablets and has the same chemical structure as Nexavar, except that a single fluorine atom has been substituted for a hydrogen atom. The new molecule had been identified in 1998 during the research collaboration period by the companies' joint research teams. Discussions with Bayer regarding Onyx's rights to fluoro-sorafenib under the companies' 1994 collaboration agreement were not productive.

Greg Giotta, Ph.D., J.D., vice president and chief legal counsel of Onyx, said, "Onyx and Bayer have had a long-standing and successful collaboration for more than 15 years. Against that background, we are disappointed that we could not resolve this matter and believe this complaint is necessary to protect our rights and the rights of our shareholders under the collaboration agreement."

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer.
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Poniard Pharmaceuticals Files Shelf Registration
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
4. Ausio Pharmaceuticals to Present at Bio(R) 2009
5. VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients
6. Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference
7. Amylin Pharmaceuticals to Present at Deutsche Bank Health Care Conference
8. Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
10. Arena Pharmaceuticals Announces First Quarter 2009 Financial Results
11. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 31, 2014 Huge event with ... future pharma industry health, analysis and forecasting   ... the closing of its most successful show to date ... 2,500 exhibitors. Held this year in Paris ... key players from 140+ countries representing every step of ...
(Date:10/31/2014)... Jeffrey T. Manuel, assistant professor in Southern ... College of Arts and Sciences, is teaming up with ... alcohol-based fuels in Illinois. , “Farmers, researchers, ... to build Illinois’ biofuels industry for decades,” Manuel said. ... state's agricultural and business history. , “Fuel alcohol ...
(Date:10/31/2014)... ENVIRON , an international ... that Dr. Harvey Clewell III has rejoined the ... closely with senior professionals in ENVIRON’s Health Sciences ... at The Hamner Institutes for Health Sciences (The ... he is Director, Center for Human Health Assessment. ...
(Date:10/30/2014)... -- Investor-Edge has initiated coverage on the ... Inc. (NASDAQ: MDVN ), Pharmacyclics Inc. (NASDAQ: ... SYN), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). Free research ... http://investor-edge.com/register . On Wednesday, October 29, 2014, ... Dow Jones Industrial Average declined 0.18%, to finish the ...
Breaking Biology Technology:CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 2CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 3CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 4CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 5CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 6SIUE History Prof Manuel Working on Biofuels Book with NCERC 2SIUE History Prof Manuel Working on Biofuels Book with NCERC 3Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5
... March 16, Shire plc (LSE: SHP, NASDAQ: ... the U.S. District Court of the Southern District of,New ... three,of Shire,s patents: U.S. Patent No. 5,968,976 (",976 Patent"); ... (",465"). , The lawsuit was ...
... AutoImmune Inc. (OTC Bulletin Board: AIMM) today reported a net ... for the three months ended December 31, 2008, compared with ... basic and diluted, for the three months ended December 31, ... loss was $345,000, or $0.02 per share basic and diluted, ...
... 16 Contamination by mycoplasmal organisms is an ... them ready sources of contamination, while rendering them ... white paper, examines how PCR mycoplasma tests ... minimizes testing delays and enable safe, high-volume biopharmaceutical ...
Cached Biology Technology:Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents 2AutoImmune Inc. Reports 2008 Fourth Quarter and Year End Financial Results 2AutoImmune Inc. Reports 2008 Fourth Quarter and Year End Financial Results 3AutoImmune Inc. Reports 2008 Fourth Quarter and Year End Financial Results 4New White Paper Examines Advanced Mycoplasma Tests - How Real-Time PCR Analysis Helps Save Time and Money for Biopharmaceutical Manufacturers 2New White Paper Examines Advanced Mycoplasma Tests - How Real-Time PCR Analysis Helps Save Time and Money for Biopharmaceutical Manufacturers 3
(Date:10/29/2014)... At a ceremony held in New York City on ... King, the American Cancer Society Professor of Genome Sciences ... and 2008 Honorary Doctor of Philosophy of Tel Aviv ... in Medical Science. , In addition to her honorary ... Lecturer at the TAU School of Medicine, and for ...
(Date:10/29/2014)... One kind of stem cell, those referred to as ... There is apparently nothing that differentiates these cells from ... namely they retain the capacity to become stem cells ... liver, an organ that hosts cells that stimulate tissue ... the case of a transplant. Knowledge of the ...
(Date:10/29/2014)... in the living world compete with members of ... how much they invest into their competitive ability. ... get access to high-quality resources, while others seem ... the lower-quality resources that are left over for ... and human societies seems to fluctuate considerably over ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2A mechanism that allows a differentiated cell to reactivate as a stem cell revealed 2Evolution of competitiveness 2Evolution of competitiveness 3
... HOUSTON (Dec. 5, 2013) A new method ... proteins may speed the process of novel drug design, ... combination of computational techniques and experimental data helped Rice ... have been hard to detect. The work ...
... CHAMPAIGN, Ill. A 115-million-year-old fossilized wasp from northeast Brazil ... organ through which it lays its eggs, looks a lot ... figs. The problem, researchers say, is that figs arose about ... report of the findings appears in the journal ...
... levers: miniaturized robots of the future will be "soft". , ... to mind are the tentacles of an octopus or the ... a crane or the inner workings of a watch. And ... organisms moving in water. The robots of the future will ...
Cached Biology News:Proteins' passing phases revealed 2Proteins' passing phases revealed 3Ancient 'fig wasp' lived tens of millions of years before figs 2'Soft' (and miniaturized) robots 2
... the ideal CO2 incubator for cell and ... embryos at or near body temperature. HERAcell ... needed to protect and grow your valuable ... incubation conditions ensure optimum culture growth. ...
SP6 RNA Polymerase, 50 l, 20 U/l ,Cap Scribe Buffer, 100 l, 5x conc....
...
... High Vacuum pumps deliver critical performance ... gas ballast control optimizes pump performance to ... glass allows for convenient checking of proper ... series of pumps is designed to work ...
Biology Products: